About RxCelerate
RxCelerate is a company based in Babraham (United Kingdom) founded in 2012. RxCelerate has completed 5 acquisitions, including Methuselah Health, Prosarix and The Cambridge Partnership. RxCelerate offers products and services including In Silico Drug Design, Antibody Discovery Platform, and Proteomics Platform. RxCelerate operates in a competitive market with competitors including Gentronix, Tigermed, Shanghai Yaocheng Health Technology, ReveraGen and Aquila BioMedical, among others.
- Headquarter Babraham, United Kingdom
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rxcelerate Limited
- Date of Incorporation 07 Nov, 2012
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
-
Investments & Acquisitions
Methuselah Health
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RxCelerate
RxCelerate offers a comprehensive portfolio of products and services, including In Silico Drug Design, Antibody Discovery Platform, and Proteomics Platform.
Computational platform for designing small molecule drugs.
Service for rapid identification of antibody leads.
Tool for protein analysis in drug development.
People of RxCelerate
Unlock access to complete
Funding Insights of RxCelerate
Investments & Acquisitions by RxCelerate
RxCelerate has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Methuselah Health, Prosarix and The Cambridge Partnership.
Investment portfolio details for RxCelerate
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Novel targets for aging-related diseases are developed via proteome research.
|
Locked | Locked | 2015 | Locked | |
|
Infrastructure and management services for virtual biotech companies are provided.
|
Locked | Locked | 2013 | Locked | |
|
Inspirational teachers and future school leaders are provided to schools.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for RxCelerate
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - RxCelerate
Detailed financials for RxCelerate
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rxcelerate Comparisons
Peer comparison for RxCelerate
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RxCelerate
RxCelerate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gentronix, Tigermed, Shanghai Yaocheng Health Technology, ReveraGen and Aquila BioMedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
In-vitro and in-vivo genetic toxicology screening services are provided.
|
|
| Locked | Locked | Locked |
Drug development and preclinical services are provided by Tigermed.
|
|
| Locked | Locked | Locked |
Clinical trial services to biopharma sector are provided.
|
|
| Locked | Locked | Locked |
Steroids for Duchenne muscular dystrophy treatment are developed.
|
|
| Locked | Locked | Locked |
Preclinical services in immunology, regeneration, neuroscience, and histology are provided.
|
|
| Locked | Locked | Locked |
Contract research on infectious disease models is conducted.
|
Detailed competitors of RxCelerate
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rxcelerate
Complete news archive for RxCelerate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RxCelerate
RxCelerate was founded in 2012 and raised its 1st funding round 12 years after it was founded.
RxCelerate is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
Founded in 2012 and based in Babraham, United Kingdom, RxCelerate operates in the biotechnology sector. Pre-clinical contract research services are provided to advance lead candidates from discovery to IND readiness. Key offerings include GLP efficacy studies, toxicology assessments, and ADME evaluations, supporting pharmaceutical development processes.
RxCelerate offers In Silico Drug Design, Antibody Discovery Platform, and Proteomics Platform.
RxCelerate has made 5 acquisitions, including Methuselah Health, Prosarix, and The Cambridge Partnership.